The CD70/CD27 pathway is critical for stimulation of an effective cytotoxic T cell response against B cell precursor acute lymphoblastic leukemia

Journal of Immunology

Volumn 182, Issue 1, 2009, Pages 718-725

  Glouchkova, Ludmila ^a,b   Ackermann, Birgit ^a   Zibert, Andree ^a   Meisel, Roland ^a   Siepermann, Meinolf ^a   Janka Schaub, Gritta E ^c   Goebel, Ulrich ^a   Troeger, Anja ^a   Dilloo, Dagmar ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD27 ANTIGEN; CD40 ANTIGEN; CD70 ANTIGEN; CD86 ANTIGEN; CD70 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; UPREGULATION; B LYMPHOCYTE; BIOSYNTHESIS; CELL DIFFERENTIATION; COCULTURE; CYTOTOXICITY TEST; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIXED LYMPHOCYTE CULTURE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; STEM CELL; TUMOR CELL CULTURE;

ANTIGENS, CD27; ANTIGENS, CD70; B-LYMPHOCYTE SUBSETS; CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOTOXICITY TESTS, IMMUNOLOGIC; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIGNAL TRANSDUCTION; STEM CELLS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 59849124888     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.1.718     Document Type: Article

References (44)

1. + T cells: a story of survival. Adv. Exp. Med. Biol. 590: 149-170.
2. Croft, M. 2003. Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev. 14: 265-273.
3. Yamada, S., K. Shinozaki, and K. Agematsu. 2002. Involvement of CD27/CD70 interactions in antigen-specific cytotoxic T-lymphocyte (CTL) activity by perforin-mediated cytotoxicity. Clin. Exp. Immunol. 130: 424-430.
4. Taraban, V. Y., T. F. Rowley, and A. Al-Shamkhani. 2004. Cutting edge: A critical role for CD70 in CD8 T cell priming by CD40-licensed APCs. J. Immunol. 173: 6542-6546.
5. Ranheim, E. A., and T. J. Kipps. 1993. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med. 177: 925-935.
6. Buhmann, R., A. Nolte, D. Westhaus, B. Emmerich, and M. Hallek. 1999. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 93: 1992-2002.
7. Trentin, L., A. Perin, M. Siviero, F. Piazza, M. Facco, C. Gurrieri, S. Galvan, F. Adami, C. Agostini, G. Pizzolo, et al. 2000. B7 costimulatory molecules from malignant cells in patients with B-cell chronic lymphoproliferative disorders trigger T-cell proliferation. Cancer 89: 1259-1268.
8. Cardoso, A. A., M. J. Seamon, H. M. Afonso, P. Ghia, V. A. Boussiotis, G. J. Freeman, J. G. Gribben, S. E. Sallan, and L. M. Nadler. 1997. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood 90: 549-561.
9. Dilloo, D., M. Brown, M. Roskrow, W. Zhong, M. Holladay, W. Holden, and M. Brenner. 1997. CD40 ligand induces an antileukemia immune response in vivo. Blood 90: 1927-1933.
10. Renard, N., M. Lafage-Pochitaloff, I. Durand, V. Duvert, L. Coignet, J. Banchereau, and S. Saeland. 1996. Demonstration of functional CD40 in B-lineage acute lymphoblastic leukemia cells in response to T-cell CD40 ligand. Blood 87: 5162-5170.
11. Harding, F. A., J. G. McArthur, J. A. Gross, D. H. Raulet, and J. P. Allison. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356: 607-609.
12. Thompson, C. B., and J. P. Allison. 1997. The emerging role of CTLA-4 as an immune attenuator. Immunity 7: 445-450.
13. Gruss, H. J., and S. K. Dower. 1995. The TNF ligand superfamily and its relevance for human diseases. Cytokines Mol. Ther. 1: 75-105.
14. + T cell priming. J. Immunol. 177: 2969-2975.
15. Bowman, M. R., M. A. Crimmins, J. Yetz-Aldape, R. Kriz, K. Kelleher, and S. Herrmann. 1994. The cloning of CD70 and its identification as the ligand for CD27. J. Immunol. 152: 1756-1761.
16. Hintzen, R. Q., S. M. Lens, G. Koopman, S. T. Pals, H. Spits, and R. A. van Lier. 1994. CD70 represents the human ligand for CD27. Int. Immunol. 6: 477-480.
17. Durkop, H., I. Anagnostopoulos, S. Bulfone-Paus, and H. Stein. 1997. Expression of several members of the TNF-ligand and receptor family on tonsillar lymphoid B cells. Br. J. Haematol. 98: 863-868.
18. Goodwin, R. G., M. R. Alderson, C. A. Smith, R. J. Armitage, T. VandenBos, R. Jerzy, T. W. Tough, M. A. Schoenborn, T. Davis-Smith, and K. Hennen. 1993. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 73: 447-456.
19. van Lier, R. A., J. Borst, T. M. Vroom, H. Klein, P. Van Mourik, W. P. Zeijlemaker, and C. J. Melief. 1987. Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J. Immunol. 139: 1589-1596.
20. Maurer, D., W. Holter, O. Majdic, G. F. Fischer, and W. Knapp. 1990. CD27 expression by a distinct subpopulation of human B lymphocytes. Eur. J. Immunol. 20: 2679-2684.
21. Arens, R., K. Tesselaar, P. A. Baars, G. M. van Schijndel, J. Hendriks, S. T. Pals, P. Krimpenfort, J. Borst, M. H. van Oers, and R. A. van Lier. 2001. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNγ-mediated B cell depletion. Immunity 15: 801-812.
22. + T cells for IL-12-induced Th1 cell development. Int. Immunol. 19: 713-718.
23. Lens, S. M., P. Drillenburg, B. F. den Drijver, G. van Schijndel, S. T. Pals, R. A. van Lier, and M. H. van Oers. 1999. Aberrant expression and reverse signalling of CD70 on malignant B cells. Br. J. Haematol. 106: 491-503.
24. Trentin, L., R. Zambello, R. Sancetta, M. Facco, A. Cerutti, A. Perin, M. Siviero, U. Basso, M. Bortolin, F. Adami, et al. 1997. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Res. 57: 4940-4947.
25. Ranheim, E. A., M. J. Cantwell, and T. J. Kipps. 1995. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 85: 3556-3565.
26. +CD25 T cells. Blood 110: 2537-2544.
27. Katayama, Y., A. Sakai, N. Oue, H. Asaoku, T. Otsuki, T. Shiomomura, R. Masuda, N. Hino, Y. Takimoto, F. Imanaka, et al. 2003. A possible role for the loss of CD27-CD70 interaction in myelomagenesis. Br. J. Haematol. 120: 223-234.
28. Nilsson, A., A. de Milito, F. Mowafi, G. Winberg, O. Bjork, E. Z. Wolpert, and F. Chiodi. 2005. Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL. Exp. Hematol. 33: 1500-1507.
29. Zheng, Z., M. Takahashi, S. Aoki, K. Toba, A. Liu, Y. Osman, H. Takahashi, N. Tsukada, N. Suzuki, K. Nikkuni, et al. 1998. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies. J. Exp. Clin. Cancer Res. 17: 251-258.
30. Tsukada, N., S. Aoki, S. Maruyama, K. Kishi, M. Takahashi, and Y. Aizawa. 1997. The heterogeneous expression of CD80, CD86 and other adhesion molecules on leukemia and lymphoma cells and their induction by interferon. J. Exp. Clin. Cancer Res. 16: 171-176.
31. + T cells. J. Immunol. 174: 710-717.
32. Schmitter, D., U. Bolliger, M. Hallek, and G. Pichert. 1999. Involvement of the CD27-CD70 co-stimulatory pathway in allogeneic T-cell response to follicular lymphoma cells. Br. J. Haematol. 106: 64-70.
33. Bashey, A., M. J. Cantwell, and T. J. Kipps. 2002. Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells. Br. J. Haematol. 118: 506-513.
34. D'Amico, G., M. Vulcano, C. Bugarin, G. Bianchi, G. Pirovano, M. Bonamino, V. Marin, P. Allavena, E. Biagi, and A. Biondi. 2004. CD40 activation of BCP-ALL cells generates IL-10-producing, IL-12-defective APCs that induce allogeneic T-cell anergy. Blood 104: 744-751.
35. + T cell formation. J. Exp. Med. 199: 1595-1605.
36. + cytotoxic T cell responses in vivo. J. Immunol. 172: 6039-6046.
37. Kelly, J. M., P. K. Darcy, J. L. Markby, D. I. Godfrey, K. Takeda, H. Yagita, and M. J. Smyth. 2002. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3: 83-90.
38. Kagi, D., B. Ledermann, K. Burki, R. M. Zinkernagel, and H. Hengartner. 1995. Lymphocyte-mediated cytotoxicity in vitro and in vivo: mechanisms and significance. Immunol. Rev. 146: 95-115.
39. Lowin, B., M. Hahne, C. Mattmann, and J. Tschopp. 1994. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370: 650-652.
40. Schroter, M., B. Lowin, C. Borner, and J. Tschopp. 1995. Regulation of Fas(Apo-1/CD95)- and perforin-mediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene bcl-2. Eur. J. Immunol. 25: 3509-3513.
41. Troeger, A., I. Schmitz, M. Siepermann, L. Glouchkova, U. Gerdemann, G. E. Janka-Schaub, K. Schulze-Osthoff, and D. Dilloo. 2007. Upregulation of c-FLIPS+R upon CD40 stimulation is associated with inhibition of CD95-induced apoptosis in primary precursor B-ALL. Blood 110: 384-387.
42. Cormary, C., E. Hiver, B. Mariame, G. Favre, and A. F. Tilkin-Mariame. 2005. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces antitumor immunity. Cancer Gene Ther. 12: 963-972.
43. Douin-Echinard, V., S. Bornes, P. Rochaix, A. F. Tilkin, J. M. Peron, J. Bonnet, G. Favre, and B. Couderc. 2000. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status. Cancer Gene Ther. 7: 1543-1556.
44. Zibert, A., C. Paris-Scholz, L. Glouchkova, B. Ackermann, M. Roskrow, and D. Dilloo. 2000. Leukemia cells transduced with HSV-1 amplicons expressing CD70 and IL-2 stimulate a protective anti-leukemic response in vivo. Blood 96: 804a.